Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Alessia Tieghi et al.|Cancer|2024Cited by 10
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case seriesFrancesca Palandri, Mario Tiribelli, Giulia Benevolo et al.|British Journal of Haematology|2024Cited by 6
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Valerio De Stefano, Fabrizio Cavalca et al.|Leukemia|2025Cited by 6
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Andrew Kuykendall, Monica Crugnola et al.|Cancer|2025Cited by 5
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Elisabetta Abruzzese, Fabrizio Cavalca et al.|Leukemia Research|2025Cited by 4